Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
19 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-03-08
Study Completion Date
2019-10-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to investigate how dietary fibre combinations affects gut physiology, particularly colonic gas production. Comparisons will be made between a single fermentable fibre (inulin), a non-fermentable fibre (psyllium) and a combination of the two. The study will also explore differences in response between diarrhoea-predominant and constipation-predominant IBS (IBS-D and IBS-C) respectively.
The participants will have a preliminary meeting to ensure they are eligible, then will attend the MRI department on 4 occasions separated by at least 1 week. They will ingest a drink with the fibre product mixed in, and will have 8 MRI scans (each lasting approximately 15 minutes).
The participants will have a preliminary meeting to ensure they are eligible, then will attend the MRI department on 4 occasions separated by at least 1 week. They will ingest a drink with the fibre product mixed in, and will have 8 MRI scans (each lasting approximately 15 minutes).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Chronic Feeding of Inulin And Methylcellulose on Colonic Fermentation
NCT06551961
Irritable Bowel Syndrome
RECRUITING
NA
Effects of Dietary Fibre in Irritable Bowel Syndrome (IBS)
NCT03803319
Irritable Bowel Syndrome
COMPLETED
NA
Effect of Modified Cellulose on Colonic Fermentation of Inulin
NCT05911347
Irritable Bowel Syndrome
COMPLETED
NA
Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?
NCT00189033
Colonic Diseases, Functional
COMPLETED
NA
Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
NCT05819281
Irritable Bowel Syndrome
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study is to investigate how dietary fibre combinations affects gut physiology, particularly colonic gas production. Comparisons will be made between a single fermentable fibre (inulin), a non-fermentable fibre (psyllium) and a combination of the two. The study will also explore differences in response between diarrhoea-predominant and constipation-predominant IBS (IBS-D and IBS-C) respectively.
This is a single-centre, 4-period, 4-treatment, placebo-controlled, crossover trial. Each treatment will be taken once by each participant, with randomisation of treatment order.
The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious.
Randomisation All participants will take all 4 fibre/ placebo preparations in this crossover trial but the order in which the participants take them will be randomised. The randomisation will be undertaken by a member of the research division who is independent of the study using the remote, online, open source software www.randomization.com. The resulting code will be retained by staff responsible for food preparation in paper form, and will not be shared with the investigator team. A paper copy will be kept by the CI in a sealed envelope.
On enrolment to the study, participants will be allotted the next available randomization sequence. No stratification is needed as in a crossover design participants act as their own controls. There will be a washout period of at least one week between each study day to minimise any carryover effect.
Expected duration of participant participation Study participants will be participating in the study for 6-8 weeks. Women will not be scanned during their menstrual period to avoid confounding of symptom responses.
The study consists of 5 visits to the Queens Medical Centre, Nottingham (QMC). Visits will be in University departments embedded in the hospital, either in the Nottingham Digestive Diseases Centre (NDDC) or the Level A annex of the Sir Peter Mansfield Imaging Centre (SPMIC).
The first visit will be to take consent, assess eligibility and record baseline covariates of interest. All subsequent visits will MRI study days, where participants will undergo a series of MRI scans and other assessments.
Visit 1 This visit will last around 30 minutes. The researcher will confirm that the potential participant has understood the information sheet and answer any remaining questions. The participant will then be assessed for eligibility against the criteria previously set out. If eligibility is confirmed, participants will be asked for details of current medication use including contraception, smoking status, and significant past medical history. Height and weight will be recorded. Participants will complete the Hospital Anxiety and Depression Scale and the Patient Health Questionnaire-12. These questionnaires measure psychological traits that have been associated with symptom response in IBS and so will be relevant covariates.
Participants will then begin a 7-day screening diary of bowel habit and symptoms. This will be used to confirm frequency of IBS symptoms and IBS subtype. Participants will complete the Rome IV diagnostic questionnaire as part of their eligibility assessment. If there is a discrepancy between diary data and participant report on the Rome IV questionnaire, then the PI may decide to exclude the participant. To reduce patient burden, it will be acceptable to return completed diaries by post (prepaid envelope), by electronic communication (scan or photo), or in person.
Participants will also be informed that their GP will be contacted, both to inform them of the subject's participation and to confirm medical details where required.
Once eligibility has been confirmed, the Participant will be enrolled and randomised to a sequence of treatments. These will be administered during Visits 2 - 5. Participants will be asked to minimise their intake of fermentable carbohydrates on the day preceding each of these visits in addition to having a standardised evening meal. A dietary advice sheet will be provided.
Visits 2 - 5: MRI Study Days MRI study days will take place in the level A annex of the SPMIC, in the QMC. Visits will be at least 1 week apart to minimise any carryover effect. Participants will fast from 8pm on the evening before the Study Day. Water will be permitted after 8pm. On the morning of the Study Day participants will not eat or drink, other than a few sips of water to assist swallowing of essential medicines.
It will be confirmed that participants remain safe, eligible and willing to take part. The participants will change into surgical scrubs, in line with scanning policy and will then complete the first set of assessments.
The assessments will be:
1. Report of gastrointestinal symptoms. Symptoms of wind/ flatulence, bloating and abdominal pain will be scored on a 7-point scale, 0 - 3 in half-integer intervals(5).
2. Measurement of breath hydrogen and methane content from a single forced exhalation, using the GastroCheck device (Bedfont, UK).
3. An MRI scan including various scan sequences (See MRI Analysis section)
After fasting assessment participants will ingest a Test Drink. This will comprise still water made up to 500mL with 50mL lemon juice (PLj, Holland\&Barrett, UK), into which the test supplement will be mixed.
The Test Fibres used will be:
A. 20g Inulin B. 20g Inulin and 20g psyllium C. 20g psyllium D. 20g dextrose (0g fibre content - placebo control)
The test drink will be administered in 2 x 250mL portions to prevent swelling of fibres. Participants will be given 10 minutes to consume the total 500mls.
Assessments will be repeated immediately after ingestion, then at intervals post-ingestion as shown in the schematic. Breath symptoms will be measured every 30 minutes for 2 hours, then hourly. MRIs will be taken immediately post ingestion, then hourly for 6 hours. After 3 hours a meal will be provided, designed to be low in fermentable carbohydrate and fibre. This will stimulate gut motility and movement of small bowel content into the colon. The whole Study Day will last around 8 hours.
At the end of the Study Day participants will be asked for an overall rating of their symptoms throughout the day, and an assessment of product acceptability on the basis of their experience (0 - 100 visual analogue scale).
In between assessments participants will be provided with a comfortable sitting area which is part of the level A annex. The participants will be advised to bring material such as magazines, books or electronic devices for entertainment. Guest access to the university's wireless internet (wifi) network will be available.
This is a single-centre, 4-period, 4-treatment, placebo-controlled, crossover trial. Each treatment will be taken once by each participant, with randomisation of treatment order.
The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious.
Randomisation All participants will take all 4 fibre/ placebo preparations in this crossover trial but the order in which the participants take them will be randomised. The randomisation will be undertaken by a member of the research division who is independent of the study using the remote, online, open source software www.randomization.com. The resulting code will be retained by staff responsible for food preparation in paper form, and will not be shared with the investigator team. A paper copy will be kept by the CI in a sealed envelope.
On enrolment to the study, participants will be allotted the next available randomization sequence. No stratification is needed as in a crossover design participants act as their own controls. There will be a washout period of at least one week between each study day to minimise any carryover effect.
Expected duration of participant participation Study participants will be participating in the study for 6-8 weeks. Women will not be scanned during their menstrual period to avoid confounding of symptom responses.
The study consists of 5 visits to the Queens Medical Centre, Nottingham (QMC). Visits will be in University departments embedded in the hospital, either in the Nottingham Digestive Diseases Centre (NDDC) or the Level A annex of the Sir Peter Mansfield Imaging Centre (SPMIC).
The first visit will be to take consent, assess eligibility and record baseline covariates of interest. All subsequent visits will MRI study days, where participants will undergo a series of MRI scans and other assessments.
Visit 1 This visit will last around 30 minutes. The researcher will confirm that the potential participant has understood the information sheet and answer any remaining questions. The participant will then be assessed for eligibility against the criteria previously set out. If eligibility is confirmed, participants will be asked for details of current medication use including contraception, smoking status, and significant past medical history. Height and weight will be recorded. Participants will complete the Hospital Anxiety and Depression Scale and the Patient Health Questionnaire-12. These questionnaires measure psychological traits that have been associated with symptom response in IBS and so will be relevant covariates.
Participants will then begin a 7-day screening diary of bowel habit and symptoms. This will be used to confirm frequency of IBS symptoms and IBS subtype. Participants will complete the Rome IV diagnostic questionnaire as part of their eligibility assessment. If there is a discrepancy between diary data and participant report on the Rome IV questionnaire, then the PI may decide to exclude the participant. To reduce patient burden, it will be acceptable to return completed diaries by post (prepaid envelope), by electronic communication (scan or photo), or in person.
Participants will also be informed that their GP will be contacted, both to inform them of the subject's participation and to confirm medical details where required.
Once eligibility has been confirmed, the Participant will be enrolled and randomised to a sequence of treatments. These will be administered during Visits 2 - 5. Participants will be asked to minimise their intake of fermentable carbohydrates on the day preceding each of these visits in addition to having a standardised evening meal. A dietary advice sheet will be provided.
Visits 2 - 5: MRI Study Days MRI study days will take place in the level A annex of the SPMIC, in the QMC. Visits will be at least 1 week apart to minimise any carryover effect. Participants will fast from 8pm on the evening before the Study Day. Water will be permitted after 8pm. On the morning of the Study Day participants will not eat or drink, other than a few sips of water to assist swallowing of essential medicines.
It will be confirmed that participants remain safe, eligible and willing to take part. The participants will change into surgical scrubs, in line with scanning policy and will then complete the first set of assessments.
The assessments will be:
1. Report of gastrointestinal symptoms. Symptoms of wind/ flatulence, bloating and abdominal pain will be scored on a 7-point scale, 0 - 3 in half-integer intervals(5).
2. Measurement of breath hydrogen and methane content from a single forced exhalation, using the GastroCheck device (Bedfont, UK).
3. An MRI scan including various scan sequences (See MRI Analysis section)
After fasting assessment participants will ingest a Test Drink. This will comprise still water made up to 500mL with 50mL lemon juice (PLj, Holland\&Barrett, UK), into which the test supplement will be mixed.
The Test Fibres used will be:
A. 20g Inulin B. 20g Inulin and 20g psyllium C. 20g psyllium D. 20g dextrose (0g fibre content - placebo control)
The test drink will be administered in 2 x 250mL portions to prevent swelling of fibres. Participants will be given 10 minutes to consume the total 500mls.
Assessments will be repeated immediately after ingestion, then at intervals post-ingestion as shown in the schematic. Breath symptoms will be measured every 30 minutes for 2 hours, then hourly. MRIs will be taken immediately post ingestion, then hourly for 6 hours. After 3 hours a meal will be provided, designed to be low in fermentable carbohydrate and fibre. This will stimulate gut motility and movement of small bowel content into the colon. The whole Study Day will last around 8 hours.
At the end of the Study Day participants will be asked for an overall rating of their symptoms throughout the day, and an assessment of product acceptability on the basis of their experience (0 - 100 visual analogue scale).
In between assessments participants will be provided with a comfortable sitting area which is part of the level A annex. The participants will be advised to bring material such as magazines, books or electronic devices for entertainment. Guest access to the university's wireless internet (wifi) network will be available.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Irritable Bowel Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
single-centre, 4 period, 4 treatment, placebo-controlled crossover trial.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Participants will be blind to the fibre product taken on each study visit. Masking will be assisted by adding lemon juice to the vehicle drink.
The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious.
The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
Inulin
Ingestion of 500ml water with 50ml lemon juice and 20g inulin
Group Type
EXPERIMENTAL
Inulin
Intervention Type
DIETARY_SUPPLEMENT
Ingestion of 500ml water with 50ml lemon juice and 20g inulin
Psyllium
Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
Group Type
ACTIVE_COMPARATOR
Psyllium
Intervention Type
DIETARY_SUPPLEMENT
Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
Inulin and Psyllium
Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
Group Type
ACTIVE_COMPARATOR
Inulin and psyllium
Intervention Type
DIETARY_SUPPLEMENT
Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
Intervention Type
DIETARY_SUPPLEMENT
Inulin
Ingestion of 500ml water with 50ml lemon juice and 20g inulin
Intervention Type
DIETARY_SUPPLEMENT
Psyllium
Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
Intervention Type
DIETARY_SUPPLEMENT
Inulin and psyllium
Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to give informed consent
* Fulfilment of the Rome IV criteria for Irritable Bowel Syndrome for at least 3 months:
* Abdominal pain at least two or more days per week.
* Pain associated with two or more of the following:
* Related to defecation on at least ≥30% of occasions
* Associated with a change in frequency of stool on ≥30% of occasions
* Associated with a change in form (appearance) of stool on ≥30% of occasions
* Symptom onset at least 6 months prior to diagnosis
* Fulfilment of the Rome IV criteria for Irritable Bowel Syndrome for at least 3 months:
* Abdominal pain at least two or more days per week.
* Pain associated with two or more of the following:
* Related to defecation on at least ≥30% of occasions
* Associated with a change in frequency of stool on ≥30% of occasions
* Associated with a change in form (appearance) of stool on ≥30% of occasions
* Symptom onset at least 6 months prior to diagnosis
Exclusion Criteria
* Pregnancy declared by candidate
* Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
* Inability to lie flat or exceed scanner limits of weight \<120kg
* Unwilling to cease use of supplementary fibre or osmotic laxatives for the duration of the study
* Unable to stop drugs known to alter GI motility or transit including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists or osmotic laxatives for 2 days before, and during, MRI study days.
* Reported alcohol intake of \>28 units/ week with daily drinking
* Intention to change smoking behaviour during the study
* History declared by the candidate of other pre-existing gastrointestinal disorders, including but not limited to:
* Inflammatory Bowel Disease
* Coeliac Disease
* Pancreatitis
* Gallstone disease (biliary colic, cholecystitis; asymptomatic presence of gallstones permitted)
* Complicated diverticulitis (asymptomatic presence of diverticula permitted)
* Cancer of the gastrointestinal tract
* Gastroparesis
* Other functional gastrointestinal disorders will be permitted as they frequently co-exist with IBS.
* Any reported history of gastrointestinal resection (excluding appendicectomy or cholecystectomy)
* Presence of an intestinal stoma
* Poor understanding of English language
* Participation of any medical trials for the past 3 months
* Judgement by the PI that the candidate who will be unable to comply with the full study protocol e.g. Diabetes, severe COPD
* Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
* Inability to lie flat or exceed scanner limits of weight \<120kg
* Unwilling to cease use of supplementary fibre or osmotic laxatives for the duration of the study
* Unable to stop drugs known to alter GI motility or transit including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists or osmotic laxatives for 2 days before, and during, MRI study days.
* Reported alcohol intake of \>28 units/ week with daily drinking
* Intention to change smoking behaviour during the study
* History declared by the candidate of other pre-existing gastrointestinal disorders, including but not limited to:
* Inflammatory Bowel Disease
* Coeliac Disease
* Pancreatitis
* Gallstone disease (biliary colic, cholecystitis; asymptomatic presence of gallstones permitted)
* Complicated diverticulitis (asymptomatic presence of diverticula permitted)
* Cancer of the gastrointestinal tract
* Gastroparesis
* Other functional gastrointestinal disorders will be permitted as they frequently co-exist with IBS.
* Any reported history of gastrointestinal resection (excluding appendicectomy or cholecystectomy)
* Presence of an intestinal stoma
* Poor understanding of English language
* Participation of any medical trials for the past 3 months
* Judgement by the PI that the candidate who will be unable to comply with the full study protocol e.g. Diabetes, severe COPD
Minimum Eligible Age
16 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Nottingham
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robin Spiller, Ph, BMBS
Role: STUDY_CHAIR
University of Nottingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nottingham
Nottingham, Nottinghamshire, United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Major G, Pritchard S, Murray K, Alappadan JP, Hoad CL, Marciani L, Gowland P, Spiller R. Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. Gastroenterology. 2017 Jan;152(1):124-133.e2. doi: 10.1053/j.gastro.2016.09.062. Epub 2016 Oct 14.
Reference Type
BACKGROUND
Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P, Marciani L, Gill SK, Warren FJ, Rossi M, Remes-Troche JM, Whelan K, Spiller RC. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut. 2022 May;71(5):919-927. doi: 10.1136/gutjnl-2021-324784. Epub 2021 Aug 5.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Nutrition to Relieve IBS Symptoms by Targeting the Microbiota
NCT04790422
COMPLETED
NA
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
NCT05990764
RECRUITING
NA
The Effect of Inulin Supplementation in Individuals With IBS-C
NCT06945302
COMPLETED
NA
Nutrition to Relieve IBS Constipation
NCT04798417
COMPLETED
NA
Effect of Butyrogenic Fibers in IBS Patients
NCT00314886
UNKNOWN
NA
The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients
NCT02254629
COMPLETED
PHASE1
The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D
NCT06543498
COMPLETED
NA
Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.
NCT05016024
COMPLETED
NA
Effect of MethylceIlulose or Psyllium on Fermentation of Inulin Assessed Using a Gas Sensing Capsule
NCT06551948
COMPLETED
NA
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
NCT03983434
TERMINATED
NA
Pre-FIBRe Study: Predeterminants of Fibre Induced Bloating Response.
NCT04802798
COMPLETED
NA
Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome
NCT01624610
COMPLETED
NA
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
NCT06668922
RECRUITING
NA
The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study
NCT01829932
COMPLETED
NA
Microbiota Profiling in IBS
NCT03720314
COMPLETED
A Study Comparing the Effectiveness and Convenience of Dietary Therapy for Irritable Bowel Syndrome (IBS)
NCT04072991
COMPLETED
NA
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
NCT01728610
COMPLETED
PHASE2
The Effect of Inulin in Irritable Bowel Syndrome
NCT06610188
COMPLETED
NA
A Novel Probiotic Mixture in Adults With IBS
NCT06610149
COMPLETED
NA
Postprandial Lipids in IBS and Nutritional Treatment
NCT05016596
COMPLETED
NA
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
NCT02545413
WITHDRAWN
PHASE3
Manipulation of Visceral Sensitivity and Immune System in IBS
NCT00418340
UNKNOWN
PHASE4
Effects of a Diet Based on Inulin-rich Vegetables on Gut Health and Nutritional Behaviour in Healthy Humans
NCT03540550
COMPLETED
NA
Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
NCT00616200
COMPLETED
NA
Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome
NCT06032117
COMPLETED